These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 27129009)

  • 1. Statistical analysis of Amenamevir (ASP2151) between pharmacokinetics and clinical efficacies with non-linear effect model for the treatment of genital herpes.
    Takada A; Katashima M; Kaibara A; Sawamoto T; Zhang W; Keirns J
    Clin Pharmacol Drug Dev; 2014 Sep; 3(5):365-70. PubMed ID: 27129009
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of ASP2151, a herpesvirus helicase-primase inhibitor, in a guinea pig model of genital herpes.
    Katsumata K; Chono K; Sudo K; Shimizu Y; Kontani T; Suzuki H
    Molecules; 2011 Aug; 16(9):7210-23. PubMed ID: 21869749
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ASP2151 for the treatment of genital herpes: a randomized, double-blind, placebo- and valacyclovir-controlled, dose-finding study.
    Tyring S; Wald A; Zadeikis N; Dhadda S; Takenouchi K; Rorig R
    J Infect Dis; 2012 Apr; 205(7):1100-10. PubMed ID: 22351940
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and pharmacodynamics of ASP2151, a helicase-primase inhibitor, in a murine model of herpes simplex virus infection.
    Katsumata K; Chono K; Kato K; Ohtsu Y; Takakura S; Kontani T; Suzuki H
    Antimicrob Agents Chemother; 2013 Mar; 57(3):1339-46. PubMed ID: 23274658
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergistic activity of amenamevir (ASP2151) with nucleoside analogs against herpes simplex virus types 1 and 2 and varicella-zoster virus.
    Chono K; Katsumata K; Suzuki H; Shiraki K
    Antiviral Res; 2013 Feb; 97(2):154-60. PubMed ID: 23261844
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Susceptibility of herpes simplex virus isolated from genital herpes lesions to ASP2151, a novel helicase-primase inhibitor.
    Katsumata K; Weinberg A; Chono K; Takakura S; Kontani T; Suzuki H
    Antimicrob Agents Chemother; 2012 Jul; 56(7):3587-91. PubMed ID: 22526302
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ASP2151, a novel helicase-primase inhibitor, possesses antiviral activity against varicella-zoster virus and herpes simplex virus types 1 and 2.
    Chono K; Katsumata K; Kontani T; Kobayashi M; Sudo K; Yokota T; Konno K; Shimizu Y; Suzuki H
    J Antimicrob Chemother; 2010 Aug; 65(8):1733-41. PubMed ID: 20534624
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Profile of anti-herpetic action of ASP2151 (amenamevir) as a helicase-primase inhibitor.
    Yajima M; Yamada H; Takemoto M; Daikoku T; Yoshida Y; Long T; Okuda T; Shiraki K
    Antiviral Res; 2017 Mar; 139():95-101. PubMed ID: 28027917
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integrative pharmacokinetic-pharmacodynamic modeling and simulation of amenamevir (ASP2151) for treatment of recurrent genital herpes.
    Takada A; Katashima M; Kaibara A; Chono K; Katsumata K; Sawamoto T; Suzuki H; Yano Y
    Drug Metab Pharmacokinet; 2016 Aug; 31(4):323-32. PubMed ID: 27461507
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of virus strains resistant to the herpes virus helicase-primase inhibitor ASP2151 (Amenamevir).
    Chono K; Katsumata K; Kontani T; Shiraki K; Suzuki H
    Biochem Pharmacol; 2012 Aug; 84(4):459-67. PubMed ID: 22687623
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amenamevir, a Helicase-Primase Inhibitor, for the Optimal Treatment of Herpes Zoster.
    Shiraki K; Yasumoto S; Toyama N; Fukuda H
    Viruses; 2021 Aug; 13(8):. PubMed ID: 34452412
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Influence of Hepatic and Renal Impairment on the Pharmacokinetics of a Treatment for Herpes Zoster, Amenamevir (ASP2151): Phase 1, Open-Label, Single-Dose, Parallel-Group Studies.
    Kusawake T; Kowalski D; Takada A; Kato K; Katashima M; Keirns JJ; Lewand M; Lasseter KC; Marbury TC; Preston RA
    Adv Ther; 2017 Dec; 34(12):2612-2624. PubMed ID: 29134428
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of ASP2151, a helicase-primase inhibitor, against thymidine kinase-deficient herpes simplex virus type 2 infection in vitro and in vivo.
    Himaki T; Masui Y; Chono K; Daikoku T; Takemoto M; Haixia B; Okuda T; Suzuki H; Shiraki K
    Antiviral Res; 2012 Feb; 93(2):301-304. PubMed ID: 22155691
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of daily valacyclovir suppression on herpes simplex virus type 2 viral shedding in HSV-2 seropositive subjects without a history of genital herpes.
    Sperling RS; Fife KH; Warren TJ; Dix LP; Brennan CA
    Sex Transm Dis; 2008 Mar; 35(3):286-90. PubMed ID: 18157071
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Helicase-primase inhibitor amenamevir for herpesvirus infection: Towards practical application for treating herpes zoster.
    Shiraki K
    Drugs Today (Barc); 2017 Nov; 53(11):573-584. PubMed ID: 29451274
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of valacyclovir on viral shedding in immunocompetent patients with recurrent herpes simplex virus 2 genital herpes: a US-based randomized, double-blind, placebo-controlled clinical trial.
    Fife KH; Warren TJ; Ferrera RD; Young DG; Justus SE; Heitman CK; Burroughs SM
    Mayo Clin Proc; 2006 Oct; 81(10):1321-7. PubMed ID: 17036557
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiviral efficacy of the helicase-primase inhibitor amenamevir in murine models of severe herpesvirus infection.
    Katsumata K; Chono K; Suzuki H
    Biochem Pharmacol; 2018 Dec; 158():201-206. PubMed ID: 30365949
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics and Safety of Amenamevir in Healthy Subjects: Analysis of Four Randomized Phase 1 Studies.
    Kusawake T; Keirns JJ; Kowalski D; den Adel M; Groenendaal-van de Meent D; Takada A; Ohtsu Y; Katashima M
    Adv Ther; 2017 Dec; 34(12):2625-2637. PubMed ID: 29134426
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics and Dialyzability of a Single Oral Dose of Amenamevir, an Anti-Herpes Drug, in Hemodialysis Patients.
    Tsuruoka S; Endo T; Seo M; Hashimoto N
    Adv Ther; 2020 Jul; 37(7):3234-3245. PubMed ID: 32440976
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HSV antivirals - current and future treatment options.
    Birkmann A; Zimmermann H
    Curr Opin Virol; 2016 Jun; 18():9-13. PubMed ID: 26897058
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.